For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. And readers have made it easy for us—it’s clear what kind of story drew the most interest.
It's not surprising: layoffs. Pure and simple, Fierce Biotech’s layoff coverage has garnered the most attention in 2024—and in 2023, too.
This year, our third iteration of the layoff tracker was the site’s most-read article, amassing more than 500,000 views. The format saw success with financing news as well, with Fierce Biotech’s fundraising tracker becoming the second most-read article this year.
The trackers are tools that both readers and writers can return to and live on as annual archives. We’ll launch new editions in 2025, but, for now, let’s unwrap our 10 top read stories for the year.
Happy holidays, and thanks for reading!
— Gabrielle Masson
- Fierce Biotech Layoff Tracker 2024
- Fierce Biotech Fundraising Tracker '24
- J&J to shut down massive Bay Area R&D facility less than 18 months after opening it
- Bristol Myers cutting $1.5B in costs in less than 2 years, with 2,200 employees impacted in 2024
- Sanofi begins 'full pipeline reprioritization' with layoffs in tow, R&D chief tells staff
- Genentech to shut down cancer immunology research department amid broader R&D rethink
- Hidden data on obesity prospect wipe $12B off Amgen market cap
- The top 10 pharma R&D budgets for 2023
- No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis
- Biotech faces a reckoning: ‘We've lost our luster in cell therapies’